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Context: Total 25-hydroxyvitaminD (25OHD) is amarker of vitaminD status and is lower in African
Americans than in whites. Whether this difference holds for free 25OHOD (f25OHD) is unclear,
considering reportedgenetic-racialdifferences invitaminDbindingprotein (DBP)usedtocalculate
f25OHD.
Objectives:Ourobjectivewas to assess racial-geographic differences in f25OHDand tounderstand
inconsistencies in racial associations with DBP and calculated f25OHD.
Design: This study used a cross-sectional design.
Setting: The general community in the United States, United Kingdom, and The Gambia were
included in this study.
Participants: Men in Osteoporotic Fractures in Men and Medical Research Council studies
(N  1057) were included.
Exposures: Total 25OHD concentration, race, and DBP (GC) genotype exposures were included.
Outcome Measures: Directly measured f25OHD, DBP assessed by proteomics, monoclonal and
polyclonal immunoassays, and calculated f25OHD were the outcome measures.
Results: Total 25OHD correlated strongly with directly measured f25OHD (Spearman r  0.84).
Measured by monoclonal assay, mean DBP in African-ancestry subjects was approximately 50%
lower than in whites, whereas DBPmeasured by polyclonal DBP antibodies or proteomic methods
was not lower in African-ancestry. Calculated f25OHD (using polyclonal DBP assays) correlated
stronglywithdirectlymeasured f25OHD (r0.80–0.83). Free25OHD,measuredor calculated from
polyclonal DBP assays, reflected total 25OHD concentration irrespective of race and was lower in
African Americans than in US whites.
Conclusions: Previously reported racial differences in DBP concentration are likely frommonoclo-
nal assay bias, as there was no racial difference in DBP concentration by other methods. This
confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in
assessing vitamin D in the general population. (J Clin Endocrinol Metab 101: 2226–2234, 2016)
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Vitamin D is a precursor of 1,25-dihydroxyvitamin D(1,25(OH)2D), with multiple effects in skeletal and
extraskeletal tissues (1, 2). Total circulating 25-hy-
droxyvitamin D (25OHD) is used to diagnose vitamin D
deficiency, but vitamin D bioavailability in extrarenal tis-
sues is thought to depend on the small portion of 25OHD
that is not bound to serum proteins. The concentration of
bioavailable 25OHD (not bound to vitamin D binding
protein [DBP]) or free 25OHD (not bound to DBP or al-
bumin)may better reflect 25OHD function (3, 4). In some
reports, stronger associations with free or bioavailable
25OHD than with total 25OHDwere reported for serum
calcium, PTH (5), bone mineral density (6), and vascular
outcomes (7), suggesting that free or bioavailable 25OHD
mayprovide amore clinically relevantmeasure.However,
others have reported no improvement over total 25OHD
(8). Nevertheless, the role of free 25OHD remains unre-
solved, as recently highlighted by the US Preventive Ser-
vices Task Force (9).
Free 25OHD is calculated from the concentrations of
total 25OHD,DBP, and albumin,with orwithout a factor
accounting for DBP genotype-specific binding affinities
(4, 6, 10, 11).DBP—orgroup-specific component (GC)—
polymorphisms (rs4588 and rs7041) give rise to threema-
jor polymorphic isoforms of DBP (GC-1F, GC-1S, and
GC-2), the frequencies of which differ globally, with
GC-1F alleles more common in populations of African
descent (12). Using DBP measured by a monoclonal
ELISA, Powe et al reported that DBPwas lower in African
Americans than in US whites (13). As a result, calculated
bioavailable 25OHD concentrations derived from those
DBP measures were similar in whites and African Amer-
icans, a finding at variance with the lower mean circulat-
ing total 25OHD concentration consistently reported in
African Americans (14, 15). The finding that low total
25OHD did not necessarily indicate low bioavailable
25OHDgainedwidespread attention in themedical and lay
press (9, 16, 17) and may have important implications for
nutritional supplementation policy. However, other publi-
cations did not report racial differences inDBP (18–21), and
issues have been raised concerning the DBP measurements
usedbyPoweetal (22,23).Thus,racialdifferences invitamin
D availability and sufficiency remain uncertain.
Tobetter understand these conflicting findings and inves-
tigate racial differences in total and free 25OHD, we con-
ducted studies in cohorts based in the United States, United
Kingdom, andTheGambia that included participants ofAf-
ricanandEuropeanancestryknowntodiffer inGCgenotype
distribution.We characterized themolecular forms of circu-
lating DBP through comparison of several DBP assays and
proteomic analysis of DBP peptides. In addition, we com-
pared total 25OHD to calculated 25OHDanddirectlymea-
sured free 25OHD and analyzed differences in concentra-
tions by geographic region, race, andGC genotype.
Materials and Methods
Osteoporotic Fractures inMen (MrOS) cohort.TheMrOS study
enrolled 5994 participants (24). Recruitment occurred in six US
communities, primarily through mass mailings. Participants were
community-dwellingmenolder than65yearsofage. Informedcon-
sent was obtained, and the institutional review board at each site
approved the study. From this cohort, 1020 men (101 African
Americans and 919 non-Hispanic whites) had measurements of
serum25OHDandDBPandhadGCgenotype.Serumfree25OHD
wasmeasured in194randomlyselectednon-Hispanicwhiteand80
African-American participants (see Supplemental Materials and
Methods). The mean age of participants was 74.8 (6.2) years in
whites and71.1 (5.4) inAfricanAmericans; andmeanbodymass
index (BMI) was 26.7 (4.6) kg/m2 in whites and 28.8 (4.7) in
African Americans. As described in the following section, age and
BMI adjustments were therefore employed to facilitate racial
comparisons.
MedicalResearchCouncil(MRC)Gambian/UKcohort.Samples
were from studies conducted atMRCKeneba, TheGambia, and
MRCHumanNutritionResearch , Cambridge, UK (19). Studies
were approved by the joint Gambian Government-MRC Ethics
Committee and the UK National Research Ethics Service, Cam-
bridge Committee, respectively. Participants gave informed,
written consent. All were healthy males, aged 25–39 years, and
Gambians (n 19)were of theMandinka ethnic group; UKmen
(n 18)were self-classified aswhite European. Plasma25OHD,
DBP, and directly measured free 25OHD concentrations were
available for all participants andGC genotypes for a subset with
sufficient DNA (Gambia, n  17; UK, n  12). There was no
racial-geographic difference in mean age of participants, which
was 29.3 (4.4) years in theUnitedKingdomand 29.1 (3.2) in
The Gambia. Mean BMI was 22.6 (2.3) kg/m2 in the United
Kingdom and 21.2 (1.9) in The Gambia.
25OHD and 1,25(OH)2D assays. In both cohorts, concentra-
tions of 25OHD and 1,25(OH)2D were measured with mass
spectrometry (19, 25, 26).
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DBP assays. DBP was measured in all samples by polyclonal
radial immunodiffusion (pRID) assay (18). In addition, two dif-
ferent polyclonal ELISA (pELISA) were used to measure DBP
concentration: GenWay (GenWay Biotech) in MrOS and Im-
mundiagnostik (Immundiagnostik AG) for the MRC study. Fi-
nally, DBP concentration was measured by monoclonal ELISA
(mELISA; R&D Systems).
Genotyping. Two nonsynonymous GC single nucleotide poly-
morphisms were used to define GC diplotypes, rs4588
(Thr436Lys) and rs7041 (Asp432Glu).
Calculation of free 25OHD. Free 25OHD concentrations were
calculated using published mathematical models (11).
Free 25OHD assay. Free concentrations of 25OHD were mea-
sured by ELISA (DIASource ImmunoAssays) (27, 28) at Future
Diagnostics Solutions. This assay was validated by comparison
with equilibrium dialysis at 37 C in 15 normal samples yielding
a correlation of 0.83. The lower limit of detectionwas 1.9 pg/ml,
and assay precision was less than 6% (29).
Proteomic analyses. Selected reaction monitoring (SRM) mass
spectometry-based assays for DBP peptides encompassing the
Thr436Lys and Asp432Glu substitutions, as well as separate
peptides with no known sequence variation, were carried out in
120 MrOS serum samples selected to represent each of the six
GC genotypes.
Further details of each method are in the Supplemental Ma-
terials and Methods.
Statistical analysis. Distributions of each 25OHD and DBP
measurewere examined for normality and outliers, and pairwise
Spearman correlations were calculated in each cohort. Differ-
ences in total 25OHD, DBP, and free 25OHD concentrations
between racial groups in each cohort were tested with unpaired
Student’s t tests and Wilcoxon rank-sum tests. GC genotype
differences inmean total 25OHD,DBP,DBPpeptideabundance,
and free 25OHD were tested by ANOVA in each cohort sepa-
rately and were followed by post hoc pairwise tests between
genotypes. Linear regression was used to test whether associa-
tions with race in each cohort persisted after age and BMI ad-
justment. Themodel R2 for each cohort was used to quantify the
proportion of variance in DBP concentration thatGC genotype
contributed for eachDBPassay.Analyseswere performed in SAS
9.4 (SAS Institute Inc) and Stata 12 (StataCorp).
Results
Total circulating 25OHDconcentrations varied by race and
geography. UK whites had the lowest mean levels, and the
mean total 25OHD was 56% higher in US whites than in
African Americans and 137% higher in Gambians than in
UK whites (Figure 1). There were similar differences in
1,25(OH)2D concentrations, albeit of smaller magnitude
(11%higher inUSwhites thanAfricanAmericans and 67%
higher inGambians thanUKwhites).MeanDBP concentra-
tions were minimally different across all groups using poly-
clonal assays, but themeanDBP concentrationmeasured by
mELISA was 54% lower in African Americans than in US
whites and 52% lower inGambians than in UKwhites (Fig-
ure1).Total25OHDconcentrationswereweaklycorrelated
with DBP, regardless of assay type (all Spearman r 0.28).
Directly measured free 25OHD concentrations were
strongly correlated with total 25OHD in all racial/geo-
graphicgroups (Figure2A; fromr0.71 inUKwhites to r
0.83 in both groups of African descent, Supplemental Table
1). Similarly, calculated free 25OHDconcentrations derived
from polyclonal measures of DBP were highly correlated
with total25OHD(Figure2B; r0.96forpRIDcalculation,
and r 0.93 for pELISA calculation Supplemental Table 1).
Concentrations of free 25OHD calculated from DBP mea-
sured by mELISA were less strongly correlated with total
25OHD or directly measured free 25OHD concentrations
(Figure 2C, Supplemental Table 1). Free 25OHD concen-
trations calculated using a GC-genotype specific affin-
ity generally had lower correlations with concentra-
tions of total 25OHD or measured free 25OHD than
that calculated using a constant affinity for all GC iso-
forms, although correlations were higher formELISA in
some groups (Supplemental Table 2).
The mean free 25OHD concentration was between
0.02%and0.09%of the total 25OHDmean in all groups.
Racial differences in free 25OHD reflected racial and
country differences in total 25OHD when free 25OHD
was directly measured or calculated based on polyclonal
DBP concentrations; US whites and Gambians had higher
free 25OHD than African Americans and UK whites, re-
spectively (Figure 1). However, when free 25OHD was
calculated with mELISA DBP, African Americans had a
higher mean concentration than US whites (Figure 1).
As expected, thereweremarked racial differences in the
distribution ofGC genotypes. Nearly all (97%) African
Americans and all Gambians had a GC-1F allele (1F1F,
1F1S, and 1F2 genotypes), whereas in whites the majority
had no 1F allele, and the predominant genotypes were
1S1S and 1S2 (Figure 3). There were striking differences
in how DBP assay results were associated with GC ge-
notypes. DBP concentrations measured by mELISA
were strongly associated withGC genotypes (Figure 4).
GC genotype accounted for 83% of the variation in
mELISA DBP. Mean DBP concentrations in those with
GC-1F1F and GC-1F2 genotypes were 2.5–3.4 M
lower than the predominant genotype, GC-1S2 (all
pairwise comparisons P .001, Supplemental Table 3).
In contrast,GC genotype accounted for only 16%of the
variation in pRID DBP, and although genotype was sig-
nificantly associated with pRID DBP (pANOVA .001),
no genotypic group differed from another by more than
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0.59M.GC genotype had little influence onDBPmea-
sured by pELISA (R2  0.09, pANOVA  .02, Figure 4,
Supplemental Table 3).
SRM-based proteomic analyses of genotypically variant
regions ofDBPdemonstrated that the amino acids predicted
bytheGCalleleswerepresent inserum(SupplementalFigure
1). Moreover, peptides from genetically nonvariant regions
were present in all samples and did not have lower abun-
dance inmenwithaGC-1Fallele (Figure5).These resultsare
consistent with DBPmeasures using pRID and pELISA, but
not with mELISA.
Discussion
Irrespective of race, geographical region, orGC genotype,
free 25OHD concentrations, both directly measured and
calculated using polyclonal DBP measures, mirror total
25OHD concentrations. We found that African Ameri-
cans consistently have lower free 25OHD and total
25OHD concentrations than US whites. We also showed
that GC genotype determines the forms of circulating DBP
peptides and strongly influences the measurement of DBP
usingamonoclonalELISA.Weposit thatauniquesensitivity
Figure 1. Total 25OHD, 1,25(OH)2D, free 25OHD, and vitamin D binding protein by race in MrOS and by racial-geographic group in MRC. 
coefficients are the age- and BMI-adjusted difference in each measure for African-American men (n 101) as compared to that of non-Hispanic white
men (n 919) in MrOS and for Gambian (n 19) compared to UK (n 18) men in MRC. Box and whisker plots show the 25th and 75th percentiles
and median. Whiskers represent 1.5 times the interquartile range. Note differences in scale for free 25OHD measures resulting from the larger range of
mELISA calculations and narrow range of directly measured free 25OHD. Comparisons were similar for calculated bioavailable 25OHD, which is strongly
correlated with free 25OHD (r 0.99). For measured free 25OHD in MrOS, African American n 80 and non-Hispanic white n 194.
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toGC-1FDBP, common in thosewithAfrican ancestry, un-
derlies the lowDBPconcentrationsassessedwith thatmono-
clonal ELISA, resulting in spuriously higher calculated free
25OHD and impeding the interpretation of racial compar-
isons. The results of several studies using the monoclonal
DBP assay to calculate free 25OHD should therefore be
reconsidered.
The recent reports (5, 13) of lower DBP concentra-
tions in African Americans and consequently similar
free 25OHD levels as in US whites despite a lower total
25OHD stimulated suggestions that concern for low
25OHDlevels inAfricanAmericans is unfoundedand that
guidelines on vitaminDandpublic health policy should be
revised according to race.Our results refute those findings
and provide several internally consistent lines of evidence
of ahigherprevalenceof vitaminD insufficiency inAfrican
Americans as based on both their free and total 25OHD.
They indicate that the guidelines (1) concerning vitaminD
and the assessment of vitamin D status on the basis of
plasma 25OHD should be applied regardless of race. Al-
though the current study did not address associations
with clinical outcomes or whether lower 25OHD con-
centrations in African Americans might be related to
important health consequences (eg, prostate cancer se-
Figure 2. Relationships between total 25OHD and free 25OHD (A–C) and between measured and calculated free 25OHD (D, E). Calculations are
the haplotype-constant estimates of free 25OHD, centered at the means and standardized (ie, each data point represents the distance from the
mean for the participant). Results for pELISA are not shown but were similar to pRID.
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verity (30) and cardiovascular mortality (31)), they do
suggest that these remain critical research questions.
Previous studies that concluded that calculated bio-
available 25OHD in African Americans is similar to US
whites despite differences in total 25OHD (13) depended
on the derivation of free 25OHD using results from a
monoclonal DBP. Here we show that this assay underes-
timates DBP concentrations in thosewithGC-1F alleles, a
genotype more common in those of African ancestry and
explains similar findings by others using the same mono-
clonal assay (5, 6, 13, 27, 32, 33). However, when DBP
was assessed using immunoassays of DBPwith polyclonal
antibodies and proteomic methods these GC-dependent
differences were not apparent, in line with other pro-
teomic data (21). The lower detection of GC-1F DBP by
mELISA, compared to relatively higher concentrations of
nonvariant DBP peptides by SRM and higher concentra-
tion in polyclonal assays, can best be explained by the
inadequate detectionofGC-1Fby themELISA.Ourdirect
measurements confirmed lower levels of free 25OHD in
African Americans, and we found evidence that the active
metabolite concentration and vitamin D activity is re-
duced (lowermean1,25(OH)2D).Aloia et al reported that
DBP concentrations measured by a polyclonal immuno-
assaywere similar in US blacks andwhites (33).However,
directly measured free 25OHD was not significantly dif-
ferent between races, despite a lower total 25OHD con-
centration in African Americans. Although we cannot ex-
plain this discrepancy,we note that this is surprising; if the
DBP concentration is similar in African Americans and
whites, given a lower total 25OHDconcentration, the law
of mass action predicts that the free concentration of
25OHD will be proportionally lower. Here it was as-
sumed that the association constant DBP-25OHD is the
same across genotypes as suggested bymost data (34–36).
If the affinityof25OHDforGC-1F is higher than forother
genotypes as suggested by one study based on the binding
affinity of a tracer for vitaminD rather than 25OHD (37),
then the free 25OHD concentration would be even lower
in African Americans.
We show that in African Americans, 25OHD con-
centrations (total and free) are lower than in US whites.
In contrast, in Gambians, total and free 25OHD con-
centrations are higher than in UKwhites. This cannot be
Figure 3. GC genotype by geographic-racial group.
Figure 4. Circulating DBP concentrations by genotype, as assessed
by mELISA (A), pRID (B), and pELISA (C). Genotype accounted for
83% of the variation in mELISA DBP and 16% for pRID and
pELISA DBP. Concentrations of DBP differed by genotype (all
pANOVA  .001), with GC-1F1F and 1F2 genotypes having the
lowest values in the mELISA. In pRID and pELISA, GC-22 had
significantly lower mean DBP than other genotypes (all pairwise
comparisons provided in Supplemental Table 3).
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explained by racial differences in DBP concentrations,
genotype, or affinity for 25OHD, but is consistent with
the differences in total 25OHD between these groups,
presumably the result of differences in their exposure to
UV radiation and dermal production of vitamin D. Al-
though our cohorts of Gambians and UK whites were
small, our results mirror those from other African and
UK studies (17, 38).
In our studies, calculated free 25OHD concentrations
were higher thandirectlymeasured values; thismaybedue
to lack of standardization of the direct measurements of
free 25OHD and DBP or due to some uncertainty in the
association constants used to calculate free 25OHD.
However, the relative racial differences in free 25OHD
were consistent for directly measured and calculated free
25OHD derived from DBP using polyclonal assays.
Although our study supports the comparability of
total 25OHD with free 25OHD in terms of racial as-
sociations, there is need to improve the understanding
of vitamin D metabolism through further evaluation of
free 25OHD and other metabolites and their clinical
relevance. Although free 25OHD represents less than
0.1%of the total 25OHDconcentration, itmay bemore
important for biological activity in most tissues. DBP
undoubtedly has a central role in vitamin D biology; it
may be involved in macrophage and osteocyte activa-
tion and may influence 25OHD concentration and me-
tabolism (3, 19). There may be particular clinical value
of free 25OHD measures in situations with large vari-
ation in circulating DBP concentrations (eg, pregnancy,
estrogen use, liver or kidney disease) (9, 27). This idea
is supported by knowledge that for
some steroid hormones (eg, testos-
terone, thyroxine) measures of the
free fraction may have more value
than total levels (39). This question
is particularly complex because
gaps remain in our understanding
of transport, storage, and distribu-
tion volume of the vitamin D me-
tabolites; moreover the role of DBP
in cellular uptake and subsequent
metabolism and activity of vitamin
D metabolites in different tissues
remains to be further explored.
Moreover, 25OHD is an interme-
diate metabolite with low affinity
for the vitamin D receptor and re-
flects tissue availability of 25OHD
for further hydroxylation into the
more active metabolite, 1,25(OH)2D.
Free1,25(OH)2Dconcentration ispo-
tentially a better reflection of its biological activity than total
1,25(OH)2D concentration (10, 40).
Because calculated free 25OHD derives from measures
of DBP, the accuracy of DBP assays in diverse populations
is critical. Analyses by GC genotype suggest that the large
racial differences in circulatingDBPconcentrationare assay-
dependent and related toGC genotype specific differences in
performance of the monoclonal assay. This was confirmed
by targeted proteomic analysis, showing that the concentra-
tions of DBP peptides are not lower in individuals with
GC-1F allele. Our results illustrate the importance of con-
sidering genetic variation in the accurate and complete de-
termination of circulating protein concentrations.
In conclusion, previously reported calculations of higher
bioavailable 25OHD in African Americans were influenced
byGC genotype-dependent variations in DBP assay perfor-
mance. In our studies, free 25OHD reflected total 25OHD,
and the mean free 25OHD concentration was significantly
lower inAfricanAmericansandUKwhites than inUSwhites
andGambians, respectively, consistentwith theirmean total
25OHDconcentration.Therefore, total25OHDcanbeused
in the general population as a marker of vitamin D status,
irrespective of race or DBP genotype. In practice, clinicians
should continue to measure total 25OHD in African Amer-
icans, and should continue to interpret lowvalues, asdefined
by the Institute of Medicine, as an indication for
supplementation.
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